J. Goldman & Co LP Makes New $629,000 Investment in C4 Therapeutics, Inc. (NASDAQ:CCCC)

J. Goldman & Co LP purchased a new position in C4 Therapeutics, Inc. (NASDAQ:CCCCGet Rating) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 25,930 shares of the company’s stock, valued at approximately $629,000. J. Goldman & Co LP owned 0.05% of C4 Therapeutics at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Virtus ETF Advisers LLC raised its position in C4 Therapeutics by 10.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,589 shares of the company’s stock worth $180,000 after acquiring an additional 546 shares during the period. Point72 Hong Kong Ltd raised its position in C4 Therapeutics by 49.7% in the fourth quarter. Point72 Hong Kong Ltd now owns 2,011 shares of the company’s stock worth $65,000 after acquiring an additional 668 shares during the period. Bank of New York Mellon Corp raised its position in C4 Therapeutics by 1.3% in the first quarter. Bank of New York Mellon Corp now owns 127,072 shares of the company’s stock worth $3,083,000 after acquiring an additional 1,601 shares during the period. DekaBank Deutsche Girozentrale raised its position in C4 Therapeutics by 10.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the company’s stock worth $477,000 after acquiring an additional 1,800 shares during the period. Finally, Tortoise Investment Management LLC bought a new position in C4 Therapeutics in the first quarter worth approximately $45,000. 80.43% of the stock is currently owned by institutional investors.

C4 Therapeutics Stock Up 1.3 %

Shares of NASDAQ CCCC opened at $11.23 on Friday. The company has a current ratio of 6.90, a quick ratio of 6.90 and a debt-to-equity ratio of 0.03. The firm’s fifty day moving average is $10.58 and its two-hundred day moving average is $12.18. C4 Therapeutics, Inc. has a 52-week low of $4.84 and a 52-week high of $51.21.

Analyst Ratings Changes

Separately, Credit Suisse Group raised their price objective on shares of C4 Therapeutics to $12.00 in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $23.33.

C4 Therapeutics Profile

(Get Rating)

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

Recommended Stories

Institutional Ownership by Quarter for C4 Therapeutics (NASDAQ:CCCC)

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.